重组人粒细胞集落刺激因子对乳腺癌化疗后骨髓抑制的疗效分析

Effect of Recombinant Human Granulocyte Colony-stimulating Factor on Myelosuppression after Chemotherapy in Breast Cancer Patients

目的该文旨在研究探讨应用重组人粒细胞集落刺激因子(recombinant human granulocyte colony-stimulating factor,rh G-CSF)对乳腺癌患者化疗后骨髓抑制的治疗效果。方法采用回顾性研究,方便选出2013年5月—2016年5月在某医院使用多西他赛(docetaxel)75 mg/m2、环磷酰胺(cyclophosphamide)500 mg/m2化疗方案的100例浸润性乳腺癌患者,在化疗第1个周期结束后1~2 d内皮下注射rh G-CSF为治疗组,化疗后1~2 d内未皮下注射rh G-CSF为对照组,评估两组化疗后骨髓抑制的程度。结果在应用rh G-CSF的50例患者中,白细胞减少症的发生率为24%,中性粒细胞减少症发生率为20%;在对照组50例患者中,二者发生率分别为80%和70%,差异有统计学意义(P<0.01)。治疗组与对照组化疗前白细胞计数差异无统计学意义(P=0.648>0.05),两组化疗前中性粒细胞计数差异无统计学意义(P=0.104>0.05);化疗后两组白细胞和中性粒细胞计数差异有统计学意义(P<0.01)。结论浸润性乳腺癌患者在第一周期化疗后1~2 d内给予rh G-CSF,能减少白细胞降低比率,使骨髓抑制得以减轻,确保化疗顺利进行。

Objective The purpose of this study was to investigate the effect of recombinant human granulocyte colony-stimulating factor（rh G-CSF）for myelosuppression in patients with breast cancer after chemotherapy. Methods Using retrospective study,Convenient selected 100 cases of invasive breast cancer patients,who use docetaxel 75mg/m2 and cyclophosphamide 500 mg/m2 chemotherapy in the hospital,between May 2013 and May 2016. After first cycles of chemotherapy,within one or two days, the patients were injected rh G-CSF as the treatment group,on the contrary,the patient weren＇t injected rh G-CSF as the control group. To evaluate the degree of myelosuppression after chemotherapy. Results The rate of leucopenia was 24% and the rate of neutropenia was 20% in the treatment group,The occurrence rate of the two index was80% and70% respectively in the control group. There was statistical significance between the two groups（P0.01）.The count of white blood cell and neutrophil was no significant difference between the treatment group（ P =0.648 0.05） and the control group before chemotherapy（P=0.1040.05）. After chemotherapy, the count of white blood cell and neutrophil of the two group was statistical significance（P0.01）. Conclusion The application of rh G-CSF in invasive breast cancer patients after first cycles of chemotherapy can reduce the incidence of white blood cell count, reduce the extent and duration of myelosuppression, and ensure the smooth progress of chemotherapy.